Nanomaterials for targeted drug delivery to cancer stem cells

Drug Metabolism Reviews

Volumn 46, Issue 2, 2014, Pages 191-206

  Orza, Anamaria ^a,b   Casciano, Daniel ^a   Biris, Alexandru ^a  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Cancer stem cells; Drug delivery; Gold nanostructures; Specific delivery

Indexed keywords

BETA CATENIN; NANOMATERIAL; NOTCH RECEPTOR; WNT PROTEIN; ANTINEOPLASTIC AGENT; DRUG CARRIER;

CANCER STEM CELL; CANCER THERAPY; CELL DESTRUCTION; CYTOLOGY; DNA DAMAGE; DRUG DELIVERY SYSTEM; HEDGEHOG; HUMAN; PROSPECTIVE STUDY; REVIEW; STEM CELL RESEARCH; TARGET CELL; WNT SIGNALING PATHWAY; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PARTICLE SIZE; PATHOLOGY; SURFACE PROPERTY;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; MOLECULAR TARGETED THERAPY; NANOSTRUCTURES; NEOPLASMS; NEOPLASTIC STEM CELLS; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84899421139     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.900566     Document Type: Review

References (187)

1. Agasti SS, You C-C, Arumugam P, Rotello VM. (2008). Structural control of the monolayer stability of water-soluble gold nanoparticles. J Mater Chem 18: 70-73.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
3. Alison MR, Lim SML, Nicholson LJ. (2011). Cancer stem cells: Problems for therapy. J Pathol 223: 148-62.
4. Alivisatos AP, Gu W, Larabell C. (2005). Quantum dots as cellular probes. Annu Rev Biomed Eng 7: 55-76.
5. Alivisatos AP, Johnsson KP, Peng X, et al. (1996). Organization of 'nanocrystal molecules' using DNA. Nature 382: 609-611.
6. Alkilany AM, Murphy CG. (2010). Toxicity and cellular uptake of gold nanoparticles: What we have learned so far. J Nanopart Res 12: 2313-2333.
7. Alkilany AM, Thompson LB, Boulos SP, et al. (2012). Goldnanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv Drug Deliv Rev 64: 190-199.
8. Allegra CA, Jessup JM, Somerfield MR, et al. (2009). American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
9. Allenspach EJ, Maillard I, Aster JC, Pear W. (2002). Notch signaling in cancer. Cancer Biol Ther 1: 466-476.
10. Bae YH, Park K, Aster JC, Pear W. (2002). Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 153: 198-205.
11. Balasubramanian R, Guo R, Mills A, Murray RW. (2005). Reaction of Au55(PPh3)12C16 with thiols yields thiolate monolayer protected Au75 clusters. J Am Chem Soc 127: 8126-8132.
12. Banzato A, Bobisse S, Rondina M, et al. (2008). Apaclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 14: 3598-3606.
13. Bao S, Wu Q, McLendon RE, et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-60.
14. Bar EE, Chaudhry A, Lin A, et al. (2007). Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524-2533.
15. Barth BM, Altlnoglu EI, Shanmugavelandy SS, et al. (2011). Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano 5: 5325-5337.
16. Basu S, Harfouche R, Soni S, et al. (2009). Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci USA 106: 7957-7961.
17. Beauchesne P. (2011). Extra-neural metastases of malignant gliomas: Myth or reality? Cancers 3: 461-477.
18. Bhardwaj G, Murdoch B, Wu D, et al. (2001). Some hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2: 172-180.
19. Binder H, Lindblom G. (2003). Charge-dependent translocation of the Trojan peptide penetration across lipid membranes. Biophys J 85: 982-995.
20. Biris AR, Simon S, Lupu D, et al. (2011). Near infrared optical absorption and corresponding thermal properties of single- and double-walled carbon nanotubes as correlated with their Raman scattering properties. Carbon 49: 4403-4411.
21. Biris AS, Boldor D, Palmer J, et al. (2009a). Nanophotothermolysis of multiple scattered cancer cells with carbon nanotubes guided by time-resolved infrared thermal imaging. J Biomed Opt 14: 021007.
22. Biris AS, Galanzha EI, Li Z, et al. (2009b). In vivo Raman flow cytometry for real-time detection of carbon nanotube kinetics in lymph, blood, and tissues. J Biomed Opt 14:021006.
23. Boiko AD, Razorenova OV, van de Rijn M, et al. (2010). Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466: 133-137.
24. Bonnet D, Dick JE. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
25. Bourseau-Guilmain E, Bejaud J, Griveau A, et al. (2011). Development and characterization of immunonanocarriers targeting the cancer stem cell marker AC133. Int J Pharm 423: 93-101.
26. Brust M, Fink J, Bethell D, et al. (1995). Synthesis and reactions of functionalised gold nanoparticles. Chem Commun 16: 1655-1656.
27. Brust M, Walker M, Bethell D, et al. (1994). Synthesis of thiolderivatised gold nanoparticles in a two-phase Liquid-Liquid system. Chem Commun 7: 801-802.
28. Burke AR, Singh RN, Carroll DL, et al. (2012). The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 33: 2961-2970.
29. Calcagno AM, Salcido CD, Gillet JP, et al. (2010). Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 102: 1637-1652.
30. Center for Disease Control and Prevention. (2012). World Cancer Day. Available from: http://www.cdc.gov/Features/WorldCancerDay/ [last accessed 7 June 2012].
31. Chen JK, Taipale J, Cooper MK, Beachy PA. (2002). Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16: 2743-2748.
32. Chen S, Murray RW. (1999). Arenethiolate monolayer-protected gold clusters. Langmuir 15: 682-689.
33. Chen Y, Bathula SR, Li J, et al. (2010). Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 285: 22639-22650.
34. Choi KY, Chung H, Min KH, et al. (2010). Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31: 106-114.
35. Cicalese A, Bonizzi G, Pasi CE, et al. (2009). The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138: 1083-1095.
36. Civenni G, Walter A, Kobert N, et al. (2011). Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 71: 3098-3109.
37. Clevers H. (2011). The cancer stem cell: Premises, promises and challenges. Nat Med 17: 313-319.
38. Connor EE, Mwamuka J, Gole A, et al. (2005). Gold nanoparticles are taken up by human cells but do not cause acute toxicity. Small 1: 325-327.
39. Cozzio A, Passegue E, Ayton PM, et al. (2003). Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17: 3029-3035.
40. Dai Q, Worden JG, Trullinger J, Huo Q. (2005). A "Nanonecklace" synthesized from monofunctionalized gold nanoparticles. J Am Chem Soc 127: 8008-8009.
41. David T. (2007). Using gold nanoparticles for catalysis. Nanotoday 2: 40-43.
42. Daya-Grosjean L, Couvé-Privat S. (2005). Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 225: 181-192.
43. Dekaney CM, Gulati AS, Garrison AP, et al. (2009). Regeneration of intestinal stem/progenitor cells following doxorubicin treatment of mice. Am J Physiol Gastrointest Liver Physiol 297: 461-470.
44. Devine DV, Wong K, Serrano K, et al. (1994). Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta 1191: 43-51.
45. Dg Marhaba R, Klingbeil P, Nuebel T, et al. (2008). CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8: 784-804.
46. Diao JJ, Cao Q. (2011). Gold nanoparticle wire and integrated wire array for electronic detection of chemical and biological molecules. AIP Adv 1:012115.
47. Dickerson EB, Dreaden EC, Huang X, et al. (2008) Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett 269: 57-66.
48. Diehn M, Cho RW, Lobo NA, et al. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783.
49. El-Ansary A, Al-Daihan S. (2009). On the toxicity of therapeutically used nanoparticles: An overview. J Toxicol 2009: 1-9.
50. Eyler CE, Rich JN. (2008). Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26: 2839-2845.
51. Fan X, Khaki L, Zhu TS, et al. (2010). Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28: 5-16.
52. Faraday M. (1857). The Bakerian Lecture: Experimental relations of gold (and other metals) to light. Phil Trans R Soc Lond 147: 145-181.
53. Feldmann G, Dhara S, Fendrich V, et al. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 67: 2187-2196.
54. Fischer M, Yen WC, Kapoun AM, et al. (2011). Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 71: 1520-1525.
55. Fischer PM, Krausz E, Lane DP. (2001). Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjug Chem 12: 825-841.
56. Ford MGJ, Mills IG, Peter BJ, et al. (2002). Curvature of clathrin-coated pits driven by epsin. Nature 419: 361-366.
57. Frank-Kamenetsky M, Zhang XM, Bottega S, et al. (2002). Smallmolecule modulators of Hedgehog signaling: Identification and characterization of Smoothened agonists and antagonists. J Biol 1:10.
58. Frens G. (1973). Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nat Phys Sci 241: 20-22.
59. Galanzha EI, Nedosekin DA, Sarimollaoglu M, et al. (2013). Photoacoustic and photothermal cytometry using photoswitchable proteins and nanoparticles with ultrasharp resonances. J Biophotonics. doi: 10.1002/jbio.201300140. [Epub ahead of print].
60. Gao X, Cui Y, Levenson RM, et al. (2004). In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22: 969-976.
61. Glazer ES, Zhu C, Massey KL, et al. (2010). Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res 16: 5712-5721.
62. Grainger SJ, Serna JV, Sunny S, et al. (2010). Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids. Mol Pharm 7: 2006-2019.
63. Gomez-Cabrero A, Wrasidlo W, Reisfeld RA. (2013). IMD-0354 targets breast cancer stem cells: A novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model. PLoS One 8:e73607. doi:10.1371/journal. pone.0073607.
64. Guo J, Zhou J, Ying X, et al. (2010). Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J Pharm Pharm Sci 13: 136-151.
65. Hahn H, Wicking C, Zaphiropoulous PG, et al. (1996). Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85: 841-851.
66. Hao E, Bailey RC, Schatz GC, et al. (2004). Synthesis and optical properties of "branched" gold nanocrystals. Nano Lett 4: 327-330.
67. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. (2008). Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9: 435-443.
68. Hausmann G, von Mering C, Basler K. (2009). The Hedgehog signaling pathway: Where did it come from. PLoS Biloloby 7:e1000146.
69. Hayashi A, Naseri A, Pennesi ME, de Juan E. (2009). Subretinal delivery of immunoglobulin G with gold nanoparticles in the rabbit eye. Jan J Ophthalmol 53: 249-256.
70. Henke G, Paulsen F, Steinbach JP, et al. (2009). Hypofractionated reirradition for recurrent malignant glioma. Strahlenther Onkol 185: 113-119.
71. Hinrichsen L, Meyerholz A, Groos S, Ungewickell EJ. (2006). Bending a membrane: How clathrin affects budding. Proc Natl Acad Sci USA 103: 8715-8720.
72. Hirschmann-Jax C, Foster AE, Wulf GG, et al. (2004). A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233.
73. Hoeijmakers JH. (2001). Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374.
74. Hostetler M, Templeton A, Murray R. (1999). Dynamics of placeexchange reactions on monolayer-protected gold cluster molecules. Langmuir 15: 3782-3789.
75. Huang X, El-Sayed IH, Qian W, El-Sayed MA. (2006). Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 128: 2115-2120.
76. Huntly BJ, Shigematsu H, Deguchi K, et al. (2004). MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6: 587-596.
77. Iancu C, Mocan L, Bele C, et al. (2011). Enhanced laser thermal ablation for the in vitro treatment of liver cancer by specific delivery of multiwalled carbon nanotubes functionalized with human serum albumin. Int J Nanomedicine 6: 129-141.
78. Ionita P, Caragheorgheopol A, Gilbert BC, Chechik V. (2004). Mechanistic study of a place-exchange reaction of Au nanoparticles with spin-labeled disulfides. Langmuir 20: 11536-11544.
79. Jamieson CH, Ailles LE, Dylla SJ, et al. (2004). Granulocytemacrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 351: 657-667.
80. Jiang J, Oberdörster G, Biswa P. (2009). Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies. J Nanopart Res 11: 77-89.
81. Jordan CT. (2009). Cancer stem cells: Controversial or just misunderstood. Cell Stem Cell 4: 203-205.
82. Kamata K, Lu Y, Xia Y. (2003). Synthesis and characterization of monodispersed core-shell spherical colloids and movable cores. J Am Chem Soc 125: 2384-2385.
83. Kanaras AG, Kamounah FS, Schaumburg K, et al. (2002). Thioalkylated tetraethylene glycol: A new ligand for water soluble monolayer protected gold clusters. Chem Commun (Camb) (20): 2294-2295.
84. Karmakar A, Iancu C, Bartos DM, et al. (2012). Raman spectroscopy as a detection and analysis tool for in vitro specific targeting of pancreatic cancer cells by EGF-conjugated single-walled carbon nanotubes. J Appl Toxicol 32: 365-375.
85. Kato T, Natsume A, Toda H, et al. (2010). Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther 17: 1363-1371.
86. Khan JA, Pillai B, Das TK, et al. (2007). Molecular effects of uptake of gold nanoparticles in HeLa cells. ChemBioChem 8: 1237-1240.
87. Khdair A, Chen D, Patil Y, et al. (2010). Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release 141: 137-144.
88. Kim TH, Mount CW, Gombotz WR, et al. (2010). The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials 31: 7386-7397.
89. Kimling J, Maier M, Okenve B, et al. (2006). Turkevich method for gold nanoparticle synthesis revisited. J Phys Chem B 110: 15700-15707.
90. Kool M, Koster J, Bunt J, et al. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088.
91. Korkaya H, Wicha MS. (2009). HER-2, notch, and breast cancer stem cells: Targeting an axis of evil. Clin Cancer Res 15: 1845-1847.
92. Krivtsov AV, Twomey D, Feng Z, et al. (2006). Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818-822.
93. Kumar A, Ma H, Zhang X, et al. (2012). Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials 33: 1180-1189.
94. Lang SH, Frame F, Collins A. (2009). Prostate cancer stem cells. J Pathol 217: 299-306.
95. Latham AH, Williams ME. (2006). Versatile routes toward functional, water-soluble nanoparticles via trifluoroethylester-PEG-thiol ligands. Langmuir 22: 4319-4326.
96. LaVan DA, McGuire T, Langer R. (2003). Small-scale systems for in vivo drug delivery. Nat Biotechnol 21: 1184-1191.
97. Lee CJ, Li C, Simeone DM. (2008). Human pancreatic cancer stem cells: Implications for how we treat pancreatic cancer. Transl Oncol 1: 14-18.
98. Lei T, Srinivasan S, Tang Y, et al. (2011). Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine 7: 324-332.
99. Lévy R. (2006). Peptide-capped gold nanoparticles: Towards artificial proteins. ChemBioChem 7: 1141-1145.
100. Li C, Heidt DG, Dalerba P, et al. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
101. Li L, Neaves WB. (2006). Normal stem cells and cancer stem cells: The Niche matters. Cancer Res 66: 4553-4557.
102. Li R, Wu R, Zhao L, et al. (2010). P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 4: 1399-1408.
103. Li RJ, Ying X, Zhang Y, et al. (2011). All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release 149: 281-291.
104. Li X, Lewis MT, Huang J, et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
105. Lim KJ, Bisht S, Bar EE, et al. (2011). A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stemlike fraction in malignant brain tumors. Cancer Biol Ther 11: 464-473.
106. Lindgren M, Hallbrink M, Prochiantz A, Langel U. (2000). Cell-penetrating peptides. Trends Pharmacol Sci 21: 99-103.
107. Liu C, Zhao G, Liu J, et al. (2009). Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release 140: 277-283.
108. Liu Y, Zhang B, Yan B. (2011). Enabling anticancer therapeutics by nanoparticle carriers: The delivery of paclitaxel. Int J Mol Sci 12: 4395-4413.
109. Liu Q, Li RT, Qian HQ, et al. (2013). Targeted delivery of miR-200c/ DOC to inhibit cancer stem cells and cancer cells by the gelatinasesstimuli nanoparticles. Biomaterials 34: 7191-7203.
110. Lu W, Arumugam SR, Senapati D, et al. (2010). Multifunctional ovalshaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano 4: 1739-1749.
111. Magnifico A, Albano L, Campaner S, et al. (2009). Tumour-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are trastuzumab sensitive. Clin Cancer Res 15: 2010-2021.
112. Maitland NJ, Collins AT. (2008). Prostate cancer stem cells: A new target for therapy. J Clin Oncol 26: 2862-2870.
113. Mamaeva V, Rosenholm JM, Bate-Eya LT, et al. (2011). Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol Ther 19: 1538-1546.
114. Manchikanti P, Bandopadhyay TK. (2010). Nanomaterials and effects on biological systems: Development of effective regulatory norms. NanoEthics 4: 77-83.
115. Matsui W, Huff CA, Wang Q, et al. (2004). Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336.
116. Matsui W, Wang Q, Barber JP, et al. (2008). Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68: 190-197.
117. Maugeri-Saccà M, Zeuner A, De Maria R. (2011). Therapeutic targeting of cancer stem cells. Front Oncol 1: 10. doi: 10.3389/fonc.2011.00010.
118. Merchant AA, Matsui W. (2010). Targeting Hedgehog - A cancer stem cell pathway. Clin Cancer Res 16: 3130-3140.
119. Mikesch JH, Steffen B, Berdel WE, et al. (2007). The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia 21: 1638-1647.
120. Milane L, Duan Z, Amiji M. (2011). Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm 8: 185-203.
121. Mocan L, Tabaran FA, Mocan T, et al. (2011). Selective ex-vivo photothermal ablation of human pancreatic cancer with albumin functionalized multiwalled carbon nanotubes. Int J Nanomedicine 6: 915-928.
122. Moitra K, Lou H, Dean M. (2011). Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89: 491-502.
123. Moon RT, Bowerman B, Boutros M, Perrimon N. (2002). The promise and perils of Wnt signaling through b-catenin. Science 296: 1644-1646.
124. Müller-Tidow C, Steffen B, Cauvet T, et al. (2004). Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 7: 2890-2904.
125. O'Brien CA, Pollett A, Gallinger S, Dick JE. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
126. Orza A, Olenic L, Pruneanu S, et al. (2010). Morphological and electrical characteristics of amino acid-AuNP nanostructured two-dimensional ensemble. Chem Phys 373: 295-299.
127. Orza A, Soritau O, Olenic L, et al. (2011). Electrically conductive gold-coated collagen nanofibers for placental-derived mesenchymal stem cells enhanced differentiation and proliferation. ACS Nano 5: 4490-4503.
128. Orza A, Soritau O, Tomuleasa C, et al. (2013). Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomedicine 8: 689-702.
129. Orza A, Mihu C, Soritau O, et al. (2014). Multistructural biomimetic substrates for controlled cellular differentiation. Nanotechnology 25: 065102.
130. Pannuti A, Foreman K, Rizzo P, et al. (2010). Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
131. Pantarotto D, Briand JP, Prato M, Bianco A. (2004). Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb) (1): 16-17.
132. Park SH, Lee Y, Han SH, et al. (2006). Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 6:3.
133. Patil ML, Zhang M, Taratula O, et al. (2009a). Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: Effect of the degree of quaternization and cancer targeting. Biomacromolecules 10: 258-266.
134. Patil Y, Sadhukha T, Ma L, Panyam J. (2009b). Nanoparticlemediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136: 21-29.
135. Patil YB, Swaminathan SK, Sadhukha T, et al. (2010). The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31: 358-365.
136. Peer D, Karp JM, Hong S, et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotech 2: 751-760.
137. Prasad B, Arumugam S, Bala T, Sastry M. (2005). Solvent-adaptable silver nanoparticles. Langmuir 21: 822-826.
138. Ranganathan P, Weaver KL, Capobianco AJ. (2011). Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer 11: 338-351.
139. Reya T, Morrison SJ, Clarke MF, Weissman IL. (2001). Stem cells, cancer and cancer stem cells. Nature 414: 105-111.
140. Sansone P, Storci G, Tavolari S, et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117: 3988-4002.
141. Schaaff T, Knight G, Shafigullin M, et al. (1998). Isolation and selected properties of a 10.4 kDa Gold:Glutathione cluster compound. J Phys Chem B 102: 10643-10646.
142. Schatton T, Murphy GF, Frank NY, et al. (2008). Identification of cells initiating human melanomas. Nature 451: 345-349.
143. Schmidt P, Kopecky C, Hombach A, et al. (2011). Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA 108: 2474-2479.
144. Shah N, Chaudhari K, Dantuluri P, et al. (2009). Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 17: 533-542.
145. Shakeri-Zadeh A, Ghasemifard M, Mansoori GA. (2010). Structural and optical characterization of folate-conjugated gold-nanoparticles. Phys E Low-dimen Syst Nanostruct 42: 1272-1280.
146. Shenoy D, Fu W, Li J, et al. (2006). Surface functionalization of gold nanoparticles using hetero-bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery. Int J Nanomed 1: 51-57.
147. Singh R, Pantarotto D, McCarthy D, et al. (2005). Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: Toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc 127: 4388-4396.
148. Singh SK, Clarke ID, Terasaki M, et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
149. Smith LM, Nesterova A, Ryan MC, et al. (2008). CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric concers. Br J Cancer 99: 100-109.
150. Snyder EL, Dowdy SF. (2004). Cell penetrating peptides in drug delivery. Pharm Res 21: 389-393.
151. Storhoff JJ, Elghanian R, Mucic RC, et al. (1998). One-pot colormetric differentiation of polynucleotides with single base imperfections using gold nanoparticle probes. J Am Chem Soc 120: 1959-1964.
152. Stupp R, Mason WP, van den Bent MJ, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolmide for glioblastoma. N Engl J Med 352: 987-996.
153. Taton TA, Mirkin CA, Letsinger RL. (2000). Scanometric DNA array detection with nanoparticle probes. Science 289: 1757-1760.
154. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. (2008). Anti- CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568-575.
155. Templeton AC, Chen S, Gross SM, Murray RW. (1999a). Water-soluble, isolable gold clusters protected by tiopronin and coenzyme a monolayers. Langmuir 15: 66-76.
156. Templeton AC, Cliffel DE, Murray RW. (1999b). Redox and flourophore functionalization of water-soluble, tiopronin-protected gold clusters. J Am Chem Soc 121: 7081-7089.
157. Templeton AC, Hostetler MJ, Kraft CT, Murray RW. (1998). Reactivity of monolayer-protected gold cluster molecules: Steric effects. J Am Chem Soc 120: 1906-1911.
158. Thompson MC, Fuller C, Hogg TL, et al. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924-1931.
159. Tiwari PM, Vig K, Dennis VA, Singh SR. (2011). Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 1: 31-63.
160. Tkachenko AG, Xie H, Coleman D, et al. (2003). Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc 125: 4700-4701.
161. Tomuleasa C, Soritau O, Orza A, et al. (2012). Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. J Gastrointestin Liver Dis 21: 187-196.
162. Turkevich J, Stevenson PC, Hillier J. (1951). A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 11: 55-75.
163. Upadhyay KK, Bhatt AN, Mishra AK, et al. (2010). The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(g-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 31: 2882-2892.
164. Valkenburg KC, Graveel CR, Zylstra-Diegel CR, et al. (2011). Wnt/ b-catenin signaling in normal and cancer stem cells. Cancers 3: 2050-2079.
165. Verma A, Guha S, Diagaradjane P, et al. (2008). Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 14: 2476-2483.
166. Verma UN, Surabhi RM, Schmaltieg A, et al. (2003). Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer. Clin Cancer Res 9: 1291-1300.
167. Vinogradov S, Wei X. (2012). Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine (Lond) 7: 597-615.
168. Von Hoff DD, LoRusso PM, Rudin CM, et al. (2009). Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361: 1164-1172.
169. Wang CH, Chiou SH, Chou CP, et al. (2011). Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 7: 69-79.
170. Wang J, Wakeman TP, Lathia JD, et al. (2010). Notch promotes radioresistance of glioma stem cells. Stem Cells 28: 17-28.
171. Wang XL, Xu R, Wu X, et al. (2009). Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol Pharm 6: 738-746.
172. Whitesides GM, Mathias JP, Seto CT. (1991). Molecular self-assembly and nanochemistry: A chemical strategy for the synthesis of nanostructures. Science 254: 1312-1319.
173. Wu W, Shen J, Banerjee P, et al. (2010). Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemophotothermal treatment. Biomaterials 31: 7555-7566.
174. Wu W, Shen J, Banerjee P, Zhou S. (2011). Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy. Biomaterials 32: 598-609.
175. Wuelfing WP, Gross SM, Miles DT, Murray RW. (1998). Nanometer gold clusters protected by surface-bound monolayers of thiolated poly(ethyleneglycol) polymer electrolyte. J Am Chem Soc 120: 12696-12697.
176. Wulf GG, Wang RY, Kuehnle I, et al. (2001). A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173.
177. Yang ZJ, Ellis T, Markant SL, et al. (2008). Medulloblastoma can be initiated by deletion of patched in cells lineage-restricted progenitors or stem cells. Cancer Cell 14: 135-145.
178. Yao HJ, Ju RJ, Wang XX, et al. (2011). The anti-tumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 32: 3285-3302.
179. You L, Kim J, He B, et al. (2006). Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect 19: 27-31.
180. Yu MK, Park J, Jon S. (2012). Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2: 3-44.
181. Yu X, Zhang Y, Chen C, et al. (2010). Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta 1805: 97-104.
182. Zaki NM, Tirelli N. (2011). Assessment of nanomaterials cytotoxicity and internalization. Methods Mol Biol 695: 243-259.
183. Zanchet D, Micheel CM, Parak WJ, et al. (2001). Electrophoretic isolation of discrete Au nanocrystal/DNA conjugates. Nano Lett 1: 32-35.
184. Zhang L, Yao HJ, Yu Y, et al. (2012). Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 33: 565-582.
185. Zhang S, Balch C, Chan MW, et al. (2008). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
186. Zhang ZY, Smith BD. (2000). High-generation polycationic dendrimers are unusually effective at distrupting anionic vesicles: Membrane bending model. Bioconjug Chem 11: 805-814.
187. Zhou P, Hatziieremia S, Elliott MA, et al. (2010). Uptake of synthetic low density lipoprotein by leukemic stem cells - A potential stem cell targeted drug delivery strategy. J Control Release 148: 380-387.